These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8832011)

  • 1. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
    Styler MJ; Crilley P; Biggs J; Moul J; Copelan E; Topolsky D; Avalos B; Penza S; Sabol P; Downs K; Szer J; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Jul; 18(1):171-6. PubMed ID: 8832011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
    Ozkaynak MF; Weinberg K; Kohn D; Sender L; Parkman R; Lenarsky C
    Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
    Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
    Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
    Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
    Morris JD; Harris RE; Hashmi R; Sambrano JE; Gruppo RA; Becker AT; Morris CL
    Bone Marrow Transplant; 1997 Nov; 20(10):871-8. PubMed ID: 9404929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.
    Rozman C; Carreras E; Qian C; Gale RP; Bortin MM; Rowlings PA; Ash RC; Champlin RE; Henslee-Downey PJ; Herzig RH; Hinterberger W; Klein JP; Prentice HG; Reiffers J; Zwaan FE; Horowitz MM
    Bone Marrow Transplant; 1996 Jan; 17(1):75-80. PubMed ID: 8673059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
    Lee JL; Gooley T; Bensinger W; Schiffman K; McDonald GB
    Biol Blood Marrow Transplant; 1999; 5(5):306-15. PubMed ID: 10534061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
    Moscardó F; Sanz GF; de La Rubia J; Jiménez C; Saavedra S; Regadera A; Andreu R; García I; Plumé G; Martínez J; Martín G; Jarque I; Sanz MA
    Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence].
    Matsuoka S; Okamoto S; Ishida A; Wakui M; Watanabe R; Moriki T; Ikeda Y; Hirabayashi N
    Rinsho Ketsueki; 1998 Feb; 39(2):139-45. PubMed ID: 9545827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of busulfan area under the curve with veno-occlusive disease following BMT.
    Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB; Heffner LT; Hillyer CD; Holland HK; Winton EF; Saral R
    Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.
    Hasegawa S; Horibe K; Kawabe T; Kato K; Kojima S; Matsuyama T; Hirabayashi N
    Bone Marrow Transplant; 1998 Dec; 22(12):1191-7. PubMed ID: 9894723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution.
    Kami M; Mori S; Tanikawa S; Akiyama H; Onozawa Y; Tanaka T; Okamoto R; Maeda Y; Sasaki T; Kaku H; Matsuura Y; Hiruma K; Sakamaki H
    Bone Marrow Transplant; 1997 Sep; 20(5):397-402. PubMed ID: 9339756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
    Bertz H; Potthoff K; Mertelsmann R; Finke J
    Bone Marrow Transplant; 1997 Jun; 19(12):1169-73. PubMed ID: 9208109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
    Erer B; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Galimberti M; Giardini C; Gaziev D; Maiello A
    Bone Marrow Transplant; 1996 Jul; 18(1):157-62. PubMed ID: 8832009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
    Cacchione A; LeMaitre A; Couanet DV; Benhamou E; Amoroso L; Simonnard N; Hartmann O
    Bone Marrow Transplant; 2008 Oct; 42(7):449-54. PubMed ID: 18587430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.